Results 51 to 60 of about 27,163 (253)
Initiating oral fingolimod treatment in patients with multiple sclerosis
Therapeutic Advances in Neurological Disorders, 2013 Fingolimod, the first oral disease-modifying therapy (DMT) approved for the treatment of multiple sclerosis (MS) and the only sphingosine 1-phosphate receptor modulator approved for any disease state, represents an important addition to the expanding DMT
Barry A. Singer
doaj +1 more source
Therapeutic potential of Fingolimod in triple negative breast cancer preclinical models
Translational Oncology, 2021 Surgery followed by a chemotherapy agent is the first-line treatment for breast cancer patients. Nevertheless, new targets are required for women with triple-negative breast cancer (TNBC) in order to improve the treatment of this aggressive cancer ...
Tristan Rupp +5 more
doaj +1 more source
Sphingolipids as emerging mediators in retina degeneration [PDF]
, 2019 The sphingolipids ceramide (Cer), sphingosine-1-phosphate (S1P), sphingosine (Sph), and ceramide-1-phosphate (C1P) are key signaling molecules that regulate major cellular functions.
Prado Spalm, Facundo Heber +3 more
core +1 more source
Advanced Healthcare Materials, EarlyView.The biomimetic nanoplatform IMNP (ETS1 pDNA/PBAE@ITP‐MM) undergoes targeted disassembly at inflammatory vascular sites to release the ETS1 plasmid (pETS1). This release initiates a cascade of effects that inhibit pathogenic pathways and support immune homeostasis. (Abbreviations: EndMT, endothelial‐to‐mesenchymal transition; EC, endothelial cell; TC, T
Feng Zhang +13 more
wiley +1 more source
Neurología, 2014 Resumen: Introducción: Actualmente, existe una ausencia de evaluaciones económicas en el manejo de la esclerosis múltiple remitente-recurrente en segunda línea.
C. Crespo +4 more
doaj +1 more source
PND20 HEALTHCARE UTILIZATION AND COSTS AMONG AD PATIENTS WITH AND WITHOUT DYSPHAGIA [PDF]
, 2003 Primer pla del bust "Al Dr. Pi i Molist".
Gabriel, S. +3 more
core +1 more source
Advanced Healthcare Materials, EarlyView.This review explores how alternative invertebrate and small‐vertebrate models advance the evaluation of nanomaterials across medicine and environmental science. By bridging cellular and organismal levels, these models enable integrated assessment of toxicity, biodistribution, and therapeutic performance.
Marie Celine Lefevre +3 more
wiley +1 more source
Acute Lymphoblastic Leukemia in a Man Treated With Fingolimod for Relapsing Multiple Sclerosis
Journal of Investigative Medicine High Impact Case Reports, 2015 A man with relapsing multiple sclerosis, treated with fingolimod 0.5 mg/d for 15 months, developed acute lymphoblastic leukemia and died 4 months after immune ablation and bone marrow allograft, from graft versus host disease.
Stanley Cohan MD, PhD +2 more
doaj +1 more source
Non-traumatic Acute Epidural Hematoma in Multiple Sclerosis Treated With Fingolimod
Frontiers in Neurology, 2019 Fingolimod acts as a functional antagonist of the sphingosine-1-phosphate receptor and is widely used for relapsing-remitting multiple sclerosis (MS).
Ryoko Fukai +6 more
doaj +1 more source
Brain Sciences, 2022 Multiple sclerosis (MS) patients receiving natalizumab and who are at risk of developing progressive multifocal leukoencephalopathy (PML) often switch to other high-efficacy disease-modifying therapies including fingolimod as a risk mitigation strategy ...
Helmut Butzkueven +10 more
doaj +1 more source